Loading your page…
肿瘤影像学
By CHEN Kailing, WANG Kun, MAO Lijuan and 5 others.
To observe the feasibility of three-dimensional contrast-enhanced ultrasound (3D-CEUS) in evaluating the inhibitory effect of regorafenib on incomplete ablation of residual cancer.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
The rabbits were randomly divided into 4 groups (n=5): incomplete ablation group (group A), incomplete ablation + targeted therapy group (group B), targeted therapy group (group C), and control group (group D). 3D-CEUS was performed on the day before treatment and 7, 14, 21, 28 d after treatment, and quantitative parameters were analyzed in vivo. VX 2 tumors were taken out at the end of the experiment for cell proliferation index (Ki-67) and CD34 immunohistochemical staining, and microvessel density (MVD) was calculated.
At 21 and 28 days after treatment, the peak intensity (PI) of group B and C was significantly lower than that before treatment (P=0.046, 0.033, respectively). Moreover, the PI of group B and group C were significantly different from that of group D (P=0.027, 0.031, respectively). At 28 d after treatment, the ascending slope (S) of group B and group C was significantly lower than that of the control group (P=0.035, 0.014, respectively). There was significant difference between group B and group A (P=0.027). At 28 d after treatment, there was no significant difference in Ki-67 proliferation index and MVD among the three groups (P＞0.05).
Quantitative analysis parameters of 3D-CEUS can reflect the efficacy of regorafenib in inhibiting the proliferation of residual cancer after incomplete ablation of VX 2 in situ orthotopic tumor.
Published in 肿瘤影像学. The abstract is shown as published and remains the work of its authors; read the full article at the source.
zhongliuyingxiangxue.com/zh/article/doi/10.19732/j.cnki.2096-6210.2024.02.009/
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
